Phase II Placebo-Controlled Study of 4-Aminosalicylic Acid for Ulcerative Colitis

This study has been completed.

First Received: February 24, 2000 Last Updated: June 23, 2005 History of Changes

Sponsor:	National Center for Research Resources (NCRR)
Collaborator:	University of Vermont
Information provided by:	Office of Rare Diseases (ORD)
ClinicalTrials.gov Identifier:	NCT00004810

Purpose

OBJECTIVES:

I. Assess the safety and efficacy of 4-aminosalicylic acid in patients with mildly to moderately severe ulcerative colitis.

Condition	Intervention	Phase
Ulcerative Colitis	Drug: -aminosalicylic acid	Phase II

Study Type:	Interventional
Study Design:	Treatment, Randomized, Safety/Efficacy Study

Resource links provided by NLM:

Genetics Home Reference related topics: Crohn disease

MedlinePlus related topics: Ulcerative Colitis

Drug Information available for: p-Aminosalicylic acid

U.S. FDA Resources

Further study details as provided by Office of Rare Diseases (ORD):

Estimated Enrollment:	30
Study Start Date:	June 1996

Detailed Description:

PROTOCOL OUTLINE: This is a randomized study. Patients are stratified by extent of disease.

Patients are randomly assigned to oral 4-aminosalicylic acid (4-ASA) or placebo administered daily for 6 weeks. Optional 4-ASA is available to all patients for up to 1 year.

Concurrent therapy with low-dose sulfasalazine, prednisone, or equivalent is allowed.

Eligibility

Ages Eligible for Study:	18 Years to 80 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

PROTOCOL ENTRY CRITERIA:

Mildly to moderately severe ulcerative colitis
Patient age: 18 to 80

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00004810

Sponsors and Collaborators

National Center for Research Resources (NCRR)

University of Vermont

Investigators

Study Chair:

Warren L. Beeken

University of Vermont

More Information

Publications:

Beeken W, Howard D, Bigelow J, Trainer T, Roy M, Thayer W, Wild G. Controlled trial of 4-ASA in ulcerative colitis. Dig Dis Sci. 1997 Feb;42(2):354-8.

Study ID Numbers:	199/12012, UVT-12012
Study First Received:	February 24, 2000
Last Updated:	June 23, 2005
ClinicalTrials.gov Identifier:	NCT00004810 History of Changes
Health Authority:	United States: Federal Government

Keywords provided by Office of Rare Diseases (ORD):

gastrointestinal disorders
rare disease
ulcerative colitis

Additional relevant MeSH terms:

Anti-Infective Agents
Gastrointestinal Diseases
Ulcer
Colonic Diseases
Inflammatory Bowel Diseases
Colitis, Ulcerative
Intestinal Diseases
Pharmacologic Actions

Anti-Bacterial Agents
Digestive System Diseases
Pathologic Processes
Therapeutic Uses
P-Aminosalicylic Acid
Antitubercular Agents
Gastroenteritis
Colitis

ClinicalTrials.gov processed this record on November 27, 2009